Expert Discussion on Safety Results of Guselkumab for Crohn’s Disease
Panelists discuss how guselkumab demonstrated a very reassuring safety profile with no new safety signals or unexpected adverse events compared with placebo.
The safety evaluation of guselkumab in the GALAXI-2 and GALAXI-3 studies revealed a highly reassuring profile with no new safety signals or unexpected adverse events beyond those previously observed in other disease indications.
Experts emphasize that uncontrolled disease itself represents the biggest safety concern, and the safety data demonstrated no meaningful differentiation from placebo across most adverse event categories.
No different monitoring protocols than standard care for Crohn’s disease patients on advanced therapies are required.
The therapy’s tolerability provides strong clinical confidence.
Author’s summary: Guselkumab shows a reassuring safety profile for Crohn’s disease.